Recombinant soluble human ACE2 (rshACE2) has been shown to bind Spike (Wang et al., 2020), can effectively neutralize SARS-CoV-2 infections (Monteil et al., 2020, Monteil et al., 2021), and the corresponding drug candidate APN01 has undergone a phase II clinical trial for the treatment of hospitalized cases of COVID-19 (ClinicalTrials.gov Identifier: NCT04335136). Here, ACE2 is linked to COVID-19.